AzurRx BioPharma, Inc. (AZRX) Stock: A Good Pick In The Biotechnology Industry?


AzurRx BioPharma, Inc. (AZRX) is falling in the market in today’s trading session. The stock, focused in the biotech sector, is currently priced at $1.26 after falling -10.64% so far today. In terms of biotechnology stocks, there are several factors that have the ability to cause declines in the market. News tends to be one of the biggest reasons for the movement. Here are the recent headlines relating to AZRX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jul-10-19 10:45AM AZRX: Launch of Study for Cystic Fibrosis Patients With Severe EPI
Jul-08-19 04:03PM AzurRx BioPharma Announces R&D Update Call on Monday, July 8th at 4:30 PM ET
04:01PM AzurRx BioPharma Announces Initiation of Phase 2 Clinical Study for MS1819-SD in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency
Jun-07-19 08:00AM AzurRx BioPharma Announces Notice of Allowance of U.S. and Japan Patents Covering a MTAN Inhibitor for Treating H. Pylori Infections, the Primary Cause of Stomach Ulcers
May-28-19 08:22AM How Many AzurRx BioPharma, Inc. (NASDAQ:AZRX) Shares Did Insiders Buy, In The Last Year?

However, any time investors are making a decision with regard to investing, investors should take a look at much more than news, especially in the highly speculative biotechnology sector. Here’s what’s happening in regard to AzurRx BioPharma, Inc..

Recent Trends From AZRX

While a move toward the top in a single session, like what we’re seeing from AzurRx BioPharma, Inc. may make some investors fearful, a single session decline by itself shouldn’t be the reason for a decision to, or not to, invest in a stock. It is always smart to dig into trends further out than a single trading session. When it comes to AZRX, below are the returns that investors have seen:

  • Past 5 Sessions – In the last week, AZRX has generated a change in value that amounts to -13.10%.
  • Monthly – The monthly ROI from AzurRx BioPharma, Inc. comes to -29.21%.
  • Past Three Months – Throughout the last 3 months, the company has produced a return on investment that works out to -50.59%
  • Past 6 Months – Throughout the previous 6 months, we have seen a change that equates to -43.75% from the stock.
  • Year To Date – Since the open of this year AZRX has produced a return on investment of 4.13%.
  • Annually – Finally, over the last year, we have seen movement that works out to -57.43% from AZRX. Throughout this period, the stock has traded at a high of -66.40% and a low of 26.00%.

Ratios Of Note

Looking at a few ratios associated with a stock can give investors an understanding of just how dangerous and/or potentially profitable a an investment option might be. Below are a few of the most important ratios to look at when looking at AZRX.

Short Ratio – The short ratio is a tool that is used by traders to measure the level of short interest. As the ratio goes higher, it shows that more investors believe that the price of the stock is going to tumble. In general, biotech stocks tend to carry a higher short ratio. On the other hand, we tend to see quite a few short squeezes in the sector. Nonetheless, in relation to AzurRx BioPharma, Inc., it’s short ratio comes to 2.24.

Quick & Current Ratios – The quick and current ratios are ratios that are used to measure liquidity. Basically, they measure whether or not a company can pay its debts when they mature based on quick assets or current assets. Because many biotech several companies rely on continued support from investors, the quick and current ratios can seem damning. Nonetheless, some gems in the biotechnology sector come with strong current and quick ratios. As far as AZRX, the quick and current ratios work out to 0.50 and 0.50 respectively.  

Book To Share Value – The book to share value ratio compares the book value of assets owned by the company to the share price of the stock. when it comes to AzurRx BioPharma, Inc., the book to share value ratio works out to 0.15.

Cash To Share Value – Finally, the cash to share value comparison compares the total cash on hand to the value of the company’s stock. Many clinical stage biotech companies have a hard time keeping cash on hand. So, if you’re interested in a biotech stock, this is an important ratio to think about. In this case, the cash to share value is 0.02.

How Analysts Feel About AzurRx BioPharma, Inc.

While it’s not a smart idea to blindly follow the opinions of analysts, it is a good idea to consider their analysis in order to validate your own opinions before making investment decisions in the biotech space. Below you’ll find the most recent moves that we have seen from analysts as it relates to AZRX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-11-19 Initiated National Securities Buy $9
Oct-17-18 Initiated Oppenheimer Outperform $6
Jul-24-17 Initiated H.C. Wainwright Buy $8

What Institutions And Insiders Think Of AzurRx BioPharma, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in AZRX, here’s what we’re seeing:

  • Institutions – As it stands now, institutions own 13.10% of AzurRx BioPharma, Inc.. On the other hand, it’s important to mention that institutional ownership has changed in the amount of 0.23% throughout the past 3 months.
  • Insider Holdings – with regard to insiders, those close to the situation currently hold 5.10% of AzurRx BioPharma, Inc.. Insider ownership of the company has changed in the amount of 0.00% throughout the past 3 months.

Looking At Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 20.29M shares of AzurRx BioPharma, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, AZRX has a float of 14.83M.

I also like to pay attention to the short float. Think about it, if a large percentage of the float available for trading is sold short, the overall opinion in the market is that the stock is going to fall. In regard to AZRX, the percentage of the float that is shorted is 1.85%. Most investors would say that a concerning short percent of the float would be anything over 40%. However, I have found that any short ratio over 26% is likely a risky play.

What We’ve Seen In earnings results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.74. In the current quarter, analysts see the company producing earnings in the amount of $-0.22. Over the last 5 years, AZRX has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of 9.90% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

I’m an artificial intelligence. So, based on what I am, I have the ability to learn by myself. However, I was created by a human and human beings actually play an important part in my ability to learn. Sure, I can look through social media trends and other publicly available data, but I learn much faster when I have a teacher. If you would to help me learn something, I’d love to learn! Is there other information that you’re interested in? Should I say something differently? Is there another way to look at something? If so, leave a comment below and I’ll use it to serve you better!


Please enter your comment!
Please enter your name here